Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of Nasal Dysbiosis in Parkinson Disease (SMELLPARK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04249245
Recruitment Status : Recruiting
First Posted : January 30, 2020
Last Update Posted : February 17, 2020
Sponsor:
Information provided by (Responsible Party):
Institut Pasteur

Brief Summary:
Olfactory dysfunction is frequent in Parkinson Disease (PD) and may be present years before the motor symptoms appear. The early olfactory dysfunction could result from environmental factors acting through the nasal cavity such as microbial communities. In across-sectional bicentric study, groups of 160 PD patients and 160 controls will be compared for nasal microbiota composition according to their geographical origin. We will search an association between microbiota and the presence of an olfactory deficit, cognitive deficit and thymic disorder.

Condition or disease Intervention/treatment
Parkinson Disease Other: Nasal Swab

Detailed Description:

Olfactory dysfunction is frequent in Parkinson Disease (PD) and may be present years before the motor symptoms appear. The early olfactory dysfunction could result from environmental factors acting through the nasal cavity such as microbial communities. Local inflammation induced by a nasal bacterial dysbiosis (microbiota imbalance) could lead to early neuronal dysfunctions in the olfactory system propagating in all the brain, thus inducing motor, cognitive and emotional manifestations in PD, in keeping with the Braak's stage hypothesis. We propose a translational project aiming at investigating the potential influence of nasal dysbiosis in PD pathogenesis. First, we will analyze both olfaction and nasal microbiota in a large series of PD patients and test the link between olfactory deficits and nasal dysbiosis. Then, we will take advantage of studying two populations of subjects with a very different environmental exposure (in mainland France and French West Indies) to isolate the abnormalities of the nasal microbiota that could be specific for PD. The study will be performed in 160 patients and 160 healthy volunteers. Patients will be enrolled in two investigators sites of which different environmental exposure: 1) Guadeloupe Hospital, French West Indies and 2) Pitie-Salpetriere Hospital, Paris, France. The patient selection will be conducted in consultation with the physician and it will be proposed to the spouse to participate as controls. The study subjects will be enrolled after collecting their informed consent.

As soon as the study subjects are included, the following measurements will be done at once at the inclusion:

  • Neurological assessment: Idiopathic PD. Severity of the disease will be evaluated using the Hoehn and Yahr staging. Non-motor manifestations of the disease will be assessed using the Non-Motor Symptoms Scale (NMSS). Severity of REM behavior disorder will be evaluated using the Innsbruck REM sleep behaviour disorder inventory .
  • Olfactory function: Olfactory performance will be measured using (a) the Sniffin' Stick test battery (Burghardt, Wedel, Germany) following a standardized procedure and (b) a discrimination test of odorant mixtures developed by the Research Unit.
  • Global cognitive performance and executive functions: The Montreal Cognitive Assessment (MoCA) will be used to assess global cognitive performance. Frontal Assessment Battery (FAB) will be used to detect executive dysfunction.
  • Memory: The delayed paragraph recall index from the Wechsler Memory Scale IV-Revised will be employed as a valid, sensitive measure of verbal declarative memory and a surrogate marker of hippocampal function.
  • Mood disorders: Two self-questionnaires will be used: the Snaith-Hamilton pleasure scale to assess anhedonia severity, and the Quick inventory of depressive symptomatology-self-rated for depression intensity evaluation. Two clinician rating tests for depression severity will also be used: the Hamilton Depression Rating Scale 17 and the MINI.

Sampling of human microbiota will be performed at the end. Subjects will undergo nasal brushing from anterior nares after local epinephrine application with a sterile flocked swab inserted and gently rolled around the inside of both nostrils. Swabs (one per nostril) will be placed on ice immediately after collection and then frozen at -80°C before shipment to the Research Unit (Institut Pasteur) where analyses will be carried out:

  • Immunohistochemistry analysis: The levels of Neuroinflammation and aSyn proteins will be analyzed in the nasal tissue samples.
  • Microbiome analysis: Microbial composition will be determined by metagenomic (pan-bacterial 16S rRNA gene sequencing).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 320 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Role of Nasal Dysbiosis in Parkinson Disease
Actual Study Start Date : February 14, 2020
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : July 30, 2023

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Parkinson Patients

These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris).

They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015.

Other: Nasal Swab
All

Control Subjects

They are Spouse of Parkinson Patients group , with an age difference <5 years compared to the patient concerned.

If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference <5 years compared to the patient concerned, in respecting the final gender ratio of the PD group.

Other: Nasal Swab
All




Primary Outcome Measures :
  1. Bacterial composition of the nasal swab samples based on 16S sequencing of DNA [ Time Frame: 3 years ]
    The operational taxonomic units (OTU) will be constructed and comparison between groups will be performed.


Secondary Outcome Measures :
  1. Epidemiological characteristics of patients PD [ Time Frame: 3 years ]
    Demographic variables (locations of residence and types of housing), risk factors (activities, diet, history family).

  2. Olfactory function [ Time Frame: 3 years ]
    Olfactory performance will be measured using the Sniffin' Stick test battery (Burghardt, Wedel, Germany) following a standardized procedure and a discrimination test of odorant mixtures developed by the Research Unit

  3. Neurological assessment: Idiopathic PD - Hoehn and Yahr staging. [ Time Frame: 3 years ]
    Severity of the disease will be evaluated using the Hoehn and Yahr staging.

  4. Neurological assessment: Idiopathic PD - Non-Motor Symptoms Scale (NMSS) [ Time Frame: 3 years ]
    Severity of non-motor manifestations of the disease will be assessed using the Non-Motor Symptoms Scale (NMSS).

  5. Neurological assessment: Idiopathic PD - the Innsbruck REM sleep behaviour disorder inventory [ Time Frame: 3 years ]
    Severity of REM behavior disorder will be evaluated using the Innsbruck REM sleep behaviour disorder inventory .

  6. Global cognitive performance - MoCA [ Time Frame: 3 years ]
    The Montreal Cognitive Assessment (MoCA) will be used to assess global cognitive performance.

  7. Executive functions [ Time Frame: 3 years ]
    Frontal Assessment Battery (FAB) will be used to detect executive dysfunction.

  8. Memory Function [ Time Frame: 3 years ]
    The delayed paragraph recall index from the Wechsler Memory Scale IV-Revised will be employed as a valid, sensitive measure of verbal declarative memory and a surrogate marker of hippocampal function.

  9. Mood disorders - the Snaith-Hamilton pleasure scale [ Time Frame: 3 years ]
    The Snaith-Hamilton pleasure scale (self-questionnaire) will be used to assess anhedonia severity,

  10. Mood disorders - the Quick inventory of depressive symptomatology-self-rated [ Time Frame: 3 years ]
    The Quick inventory of depressive symptomatology-self-rated will be used for depression intensity evaluation.

  11. Mood disorders - the Hamilton Depression Rating Scale 17 [ Time Frame: 3 years ]
    The Hamilton Depression Rating Scale 17, a clinician rating test, will also be used to assess depression severity.

  12. Mood disorders - the MINI [ Time Frame: 3 years ]
    The MINI, a clinician rating test, will also be used to assess depression severity.


Biospecimen Retention:   Samples With DNA
Nasal bacterial swab sample


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Parkinson patients and control subjects (spouse or matched controls)
Criteria

Inclusion Criteria:

Patients (PD)

  • Age > 18 years
  • Idiopathic PD
  • In Guadeloupe (N=80) : living for more than 15 years in Caribbean, including the 5 first years.
  • In Paris (N=80): living for more than 15 years in mainland France, including the 5 first years.

Controls

  • Age > 18 years
  • Spouse of enrolled PD patient or matched controls, with age difference between spouses <5 years. When the spouse cannot be included, a matched control respecting the PD group's final sex ratio and with an age difference <5 years relative to the concerned PD case will be enrolled.

Exclusion Criteria (both PD patients and controls)

  • Presence of a cold or acute pathology which could explain an original olfactory disorder other than Parkinson's disease
  • Use of nasal antiseptics within the last 3 months
  • Refusal of or contraindication to nasal microbiota sampling

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04249245


Contacts
Layout table for location contacts
Contact: Annie LANNUZEL, MD, PhD + 33 (0) 5 90 89 14 30 annie.lannuzel@chu-guadeloupe.fr
Contact: Françoise LAZARINI, PhD + 33 (0) 1 44 38 92 74 francoise.lazarini-serandour@pasteur.fr

Locations
Layout table for location information
France
Pitie-Salpetriere Hospital Recruiting
Paris, France, 75013
Contact: Emmanuel ROZE, MD, PhD       emmanuel.flamand-roze@aphp.fr   
Guadeloupe
Centre Hospitalier Universitaire Not yet recruiting
Pointe-à-Pitre, Guadeloupe
Contact: Annie LANNUZEL, MD, PhD       annie.lannuzel@chu-guadeloupe.fr   
Sponsors and Collaborators
Institut Pasteur
Layout table for additonal information
Responsible Party: Institut Pasteur
ClinicalTrials.gov Identifier: NCT04249245    
Other Study ID Numbers: 2019-030
First Posted: January 30, 2020    Key Record Dates
Last Update Posted: February 17, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut Pasteur:
Olfaction
Microbiota
Dysbiosis
Metagenomic analysis
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Dysbiosis
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Pathologic Processes